Use your antibodies-online credentials, if available.
The protein encoded by SERPINC1 is a plasma protease inhibitor and a member of the serpin superfamily. 再加上，我们可以发Serine (Or Cysteine) Peptidase Inhibitor, Clade C (Antithrombin), Member 1 试剂盒 (68) 和 Serine (Or Cysteine) Peptidase Inhibitor, Clade C (Antithrombin), Member 1 蛋白 (33)和数多这个蛋白质的别的产品。
Showing 10 out of 289 products:
Dog (Canine) Polyclonal SERPINC1 Primary Antibody for WB - ABIN610759
Cool, Normant, Shen, Chen, Pannell, Zhang, Loh: Carboxypeptidase E is a regulated secretory pathway sorting receptor: genetic obliteration leads to endocrine disorders in Cpe(fat) mice. in Cell 1997
Show all 4 Pubmed References
Human Polyclonal SERPINC1 Primary Antibody for IHC, IHC (p) - ABIN4352910
Kuusisto, Haapasaari, Remes, Bloigu, Karihtala, Turpeenniemi-Hujanen, Kuittinen: Antithrombin III is probably not a suitable biomarker for diagnosis of primary central nervous system lymphoma. in Annals of hematology 2015
Show all 2 Pubmed References
Study identified one new small deletion within AT, which results in the loss of four amino acids (INEL) and is located at strand 3 of beta-sheet A, a region highly conserved in SERPINC1. This mutation leads to type I AT deficiency by promoting the intracellular retention of AT, which induces ER stress.
It was our aim to identify mutations in SERPINC1 causing transient antithrombin deficiency. SERPINC1 was sequenced in 214 cases with a positive test for antithrombin deficiency, including 67 with no deficiency in the sample delivered to our laboratory. The p.Val30Glu mutation (Antithrombin Dublin) was identified in five out of these 67 cases, as well as in three out of 127 cases with other SERPINC1 mutations.
different types of SERPINC1 mutations may play different roles in the development of VTE
aberrant N-glycosylation causing a recessive or transient antithrombin deficiency is a new form of thrombophilia that does not have a SERPINC1 gene defect
evaluation of serum proteins reveals that SERPINA1 (显示 SERPINA1 抗体), SERPINA3 (显示 SERPINA3 抗体) and SERPINC1 could be useful to discriminate healthy from colorectal carcinoma patients with a high sensitivity and specificity
The results this study reveal several novel mutations to the already growing list of SERPINC1 mutations, thereby adding to our knowledge of the molecular background of antithrombin deficiency.
Data indicate that all patients suffered from homozygous antithrombin (AT) deficiency caused by the mutation p.Leu131Phe in the AT gene (SERPINC1).
Studies indicate that antithrombin III (ATIII) and its gene SerpinC1 may be related to many diseases, including hypertension and kidney diseases.
The odds ratio of developing idiopathic fatal pulmonary embolism as a variant carrier for SERPINC1 is 144.2 (95% CI, 26.3-779.4; P = 1.7 x 10- 7).
In Hungary, the founder mutation, ATBp3, is the most common Antithrombin deficiency
RNA interference of Serpinc1 and/or Proc allows for evaluation of the function of these genes in vivo and provides a novel, controlled mouse model for spontaneous venous thrombosis.
ATIII may be protective in HIV-1 disease by inhibiting HIV-1 replication
The protein encoded by this gene is a plasma protease inhibitor and a member of the serpin superfamily. This protein inhibits thrombin as well as other activated serine proteases of the coagulation system, and it regulates the blood coagulation cascade. The protein includes two functional domains: the heparin binding-domain at the N-terminus of the mature protein, and the reactive site domain at the C-terminus. The inhibitory activity is enhanced by the presence of heparin. More than 120 mutations have been identified for this gene, many of which are known to cause antithrombin-III deficiency.
, serine (or cysteine) proteinase inhibitor, clade C (antithrombin), member 1
, serpin peptidase inhibitor, clade C (antithrombin), member 1
, anti-thrombin 3
, serpin C1
, serpin peptidase inhibitor, clade C, member 1
, antithrombin III
, serine (or cysteine) peptidase inhibitor, clade C (antithrombin), member 1